Generex Biotechnology Corp Receivables Turnover Ratio (GNBT), from the third quarter 2021 to the third quarter 2020 current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Generex Biotechnology Corp  (GNBT)
 

Generex Biotechnology Accounts Receivables Turnover Ratio from the third quarter 2021 to the third quarter 2020

Quarterly Results, Trends, Rankings, Statistics


Generex Biotechnology Corp's ability to collect accounts receivable sequentially worsen to 20.91, indicating more challenging environment then in the second quarter 2021, but still, it is a far cry from any concerns. Average collection period, for Generex Biotechnology's accounts receivable remained unchanged at 17 days, in the Apr 30 2021 quarter.

If we take a look into Healthcare sector Generex Biotechnology Corp achieved the highest receivable turnover ratio. While receivables turnover ratio remained unchanged relative to the previous period at no. .

What is Receivable Turnover Ratio?
What is Generex Biotechnology Corp Selling?


What is Receivable Turnover Ratio?




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GNBT Receivables Turnover Ratio (Apr 30 2021)
III. Quarter		 (Jan 31 2021)
II. Quarter		 (Oct 31 2020)
I. Quarter		 (Jul 31 2020)
IV. Quarter		 (Apr 30 2020)
III. Quarter
Y / Y Receivable Change -63.17 % -29.35 % 406.54 % -90.86 % -93.82 %
Y / Y Revenue Change -95.85 % - -87.75 % - -54.37 %
Receivable Turnover Ratio (TTM) 20.91 20.97 23.64 33.97 0.55
GNBT's Total Ranking # # # # #
Accounts Receivable average collection period days 17 17 15 11 658
Seq. Receivable Change -69.14 % -7.85 % 11.56 % 16.11 % -40.81 %
Seq. Revenue Change - - -96.92 % 476.28 % -41.84 %


Receivable Turnover Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #

Receivable Turnover Ratio Statistics
High Average Low
0 0 0
 





GNBT Company Profile • Back to GNBT Efficiency Comparisons • Compare GNBT Receivables Turnover Ratio to its Competitors

Financial Statements
Generex Biotechnology's Accounts Receivable $ 0 Millions Visit GNBT's Balance sheet
Generex Biotechnology's Sales TTM $ 3 Millions Visit GNBT's Income Statement
Sources of GNBT's Revenues Visit GNBT's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
GNBT's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
GNBT's Growth Rates GNBT's Roa GNBT's Inventory Turnover Ratio GNBT's Dividend Comparisons
GNBT's Profitability Ratios GNBT's Roi GNBT's Asset Turnover Ratio GNBT's Dividend Growth
GNBT's Valuation Ratios GNBT's Roe GNBT's Financial Strength Ratios GNBT's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Apr 30 2021, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Apr 30 2021 Receivable at quarter ending Apr 30 2021
Logicmark Inc  149.95 $ 10.137  Millions$ 0.068  Millions
Arcus Biosciences Inc   148.93 $ 85.228  Millions$ 0.572  Millions
Recursion Pharmaceuticals Inc   144.34 $ 2.562  Millions$ 0.018  Millions
Eton Pharmaceuticals Inc   139.37 $ 12.125  Millions$ 0.087  Millions
Aurinia Pharmaceuticals Inc   125.69 $ 108.944  Millions$ 0.867  Millions
Vystar Corporation  120.95 $ 27.915  Millions$ 0.231  Millions
Sigilon Therapeutics Inc   84.51 $ 2.958  Millions$ 0.035  Millions
H cyte Inc  80.05 $ 1.510  Millions$ 0.019  Millions
Orthofix Medical Inc   76.70 $ 407.332  Millions$ 5.311  Millions
Lifevantage Corp  76.64 $ 224.772  Millions$ 2.933  Millions
Zeo Scientifix Inc   73.54 $ 4.314  Millions$ 0.059  Millions
Lifemd Inc   71.84 $ 51.187  Millions$ 0.713  Millions
Cardiff Lexington Corporation  68.03 $ 3.268  Millions$ 0.048  Millions
Tvardi Therapeutics Inc   56.45 $ 128.924  Millions$ 2.284  Millions
Guardion Health Sciences Inc   56.39 $ 1.877  Millions$ 0.033  Millions
Wearable Health Solutions, Inc.  55.32 $ 1.346  Millions$ 0.024  Millions
Cardax Inc   54.50 $ 0.501  Millions$ 0.009  Millions
Endonovo Therapeutics Inc   51.00 $ 0.131  Millions$ 0.003  Millions
Chemocentryx Inc.  50.41 $ 134.114  Millions$ 2.660  Millions
Immunogen inc   49.36 $ 134.718  Millions$ 2.729  Millions
Sonida Senior Living Inc   48.63 $ 339.383  Millions$ 6.978  Millions
Grapefruit Usa Inc   47.92 $ 3.630  Millions$ 0.076  Millions
Nature s Sunshine Products inc   47.07 $ 391.700  Millions$ 8.321  Millions
Healthlynked Corp  46.65 $ 6.581  Millions$ 0.141  Millions
G1 Therapeutics Inc   45.04 $ 59.503  Millions$ 1.321  Millions
U S Physical Therapy Inc  41.65 $ 417.871  Millions$ 10.033  Millions
Verastem Inc   39.52 $ 84.466  Millions$ 2.137  Millions
Editas Medicine Inc   37.97 $ 91.508  Millions$ 2.410  Millions
Novavax inc   37.15 $ 643.168  Millions$ 17.313  Millions
Prothena Corporation Public Limited Company  37.11 $ 0.872  Millions$ 0.024  Millions

Date modified: 2026-06-22T14:32:22+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.